IL97909A - Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences - Google Patents

Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences

Info

Publication number
IL97909A
IL97909A IL97909A IL9790991A IL97909A IL 97909 A IL97909 A IL 97909A IL 97909 A IL97909 A IL 97909A IL 9790991 A IL9790991 A IL 9790991A IL 97909 A IL97909 A IL 97909A
Authority
IL
Israel
Prior art keywords
consequences
treatment
pharmaceutical compositions
monoclonal antibodies
compositions containing
Prior art date
Application number
IL97909A
Other versions
IL97909A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL97909A0 publication Critical patent/IL97909A0/en
Publication of IL97909A publication Critical patent/IL97909A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of anti-TNF antibodies to treat ischaemic and its sequelae, is claimed, especially when the ischaemia is an infarct or results from transplantation.
IL97909A 1990-04-25 1991-04-22 Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences IL97909A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013114 1990-04-25
DE4037604A DE4037604A1 (en) 1990-04-25 1990-11-27 Use of anti-TNF antibodies to treat ischaemia and its sequelae - esp. to increase survival rate after myocardial infarct and transplants

Publications (2)

Publication Number Publication Date
IL97909A0 IL97909A0 (en) 1992-06-21
IL97909A true IL97909A (en) 1997-09-30

Family

ID=25892502

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97909A IL97909A (en) 1990-04-25 1991-04-22 Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences

Country Status (7)

Country Link
EP (1) EP0453898B1 (en)
JP (1) JPH04364133A (en)
AT (1) ATE123226T1 (en)
DE (2) DE4037604A1 (en)
DK (1) DK0453898T3 (en)
ES (1) ES2073059T3 (en)
IL (1) IL97909A (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE4307508A1 (en) * 1993-03-10 1994-09-15 Knoll Ag Use of anti-TNF antibodies as a medicine in the treatment of heart failure (heart muscle weakness)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI556829B (en) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating tnfα-related disorders
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
TWI392684B (en) 2006-04-05 2013-04-11 Abbott Biotech Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
AU626572B2 (en) * 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin

Also Published As

Publication number Publication date
EP0453898A3 (en) 1991-12-18
ES2073059T3 (en) 1995-08-01
ATE123226T1 (en) 1995-06-15
DK0453898T3 (en) 1995-10-09
IL97909A0 (en) 1992-06-21
DE4037604A1 (en) 1991-10-31
EP0453898A2 (en) 1991-10-30
JPH04364133A (en) 1992-12-16
EP0453898B1 (en) 1995-05-31
DE59105609D1 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
IL97909A (en) Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
IL103981A0 (en) Pharmaceutical compositions for treatment of multiple sclerosis
ES2099158T3 (en) TREATMENT OF REJECTION OF TRANSPLANTS OR AUTOIMMUNE DISEASES AND COMPLEX OF THE GENERAL FORMULA X-PRO-Y-BOROPRO ASSOCIATED WITH THE SAME.
DE69206341D1 (en) Procedure for the treatment of BCTMP / CTMP wastewater.
DE69316948D1 (en) Soluble ligands for CD40
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
GR3026219T3 (en) Mouse monoclonal antibodies
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
DE3870508D1 (en) COMPOSITION FOR TREATING THE HAIR.
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
DE69314234D1 (en) Preserved polysiloxane emulsion for the treatment of tissues
DE69426767D1 (en) Anti idiotypic antibodies to gonococci and methods and compositions using them.
DE69428272T2 (en) LO-CD2A ANTIBODIES AND THEIR USE FOR INHIBITING T-CELL ACTIVATION AND GROWTH
ATE222927T1 (en) MONOCLONAL ANTIBODIES AGAINST TUMOR CYTOTOXIC FACTOR II (TCF-II)
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
DE520834T1 (en) Pharmaceutical composition containing PP14 or antibodies against PP14 for the treatment of immune system disorders.
DE59200730D1 (en) Process for the preparation of N - [(2-chloropyridin-5-yl) methyl] ethylenediamine.
SE8203433L (en) Foldable bedding or seating base - comprises heat-insulated underlay which folds to form storage compartments
IT8323821A0 (en) SWAB FOR SAMPLES FROM THE THROAT OR OTHER PARTS OF THE HUMAN BODY WITH TRANSPORT MEDIUM.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees